University of Pennsylvania
The University of Pennsylvania, founded in 1740 and located in Philadelphia, is a prestigious non-profit educational institution known for its commitment to producing future leaders through comprehensive liberal arts and sciences education. It offers over 140 undergraduate programs and more than 180 graduate programs across diverse fields, including anthropology, engineering, and women’s studies. The university emphasizes social outreach, providing over 300 volunteer opportunities and 160 academic community service courses, coordinated through initiatives like the Civic House and the Fox Leadership program. As a member of the Ivy League, Penn maintains competitive admissions standards that require prospective students to submit both the University application and standardized test scores. Financial aid is awarded based on need, ensuring access to education without the burden of loans. The university's focus on research and community service enriches the academic experience, fostering a spirit of engagement and leadership among its students.
Interius BioTherapeutics
Series A in 2021
Interius BioTherapeutics is a biopharmaceutical company that targets cancer. The company spun out the University of Pennsylvania and is targeting cancer.
Tmunity Therapeutics, Inc. is a bio-therapeutics company based in Philadelphia, Pennsylvania, focused on developing innovative immunotherapies for cancer, infectious diseases, and autoimmune disorders. Founded in 2015, the company specializes in harnessing the potential of T cells through the creation of novel T Cell Receptor (TCR) engineered T cells, regulatory T cells (Treg), and universal engineered T cell platforms. These products are designed to provide superior control over T cell activation and direction in vivo. Tmunity employs proprietary technologies for the activation, expansion, and genetic engineering of T cells derived from peripheral blood, cord blood, and tumors. The company's expert founding team has extensive experience in T-cell biology, manufacturing, regulatory affairs, and clinical development, enabling them to efficiently advance personalized next-generation immunotherapies into clinical trials. Tmunity's robust manufacturing platform has demonstrated success in supporting multi-center clinical studies across a variety of therapeutic areas.
Behavior Change for Good Initiative is solving the mystery of enduring behavior change offers an enormous opportunity to improve lives.
Avisi Technologies Inc. is focused on developing innovative solutions to combat glaucoma, a leading cause of irreversible blindness. The company has created VisiPlate, a next-generation aqueous shunt designed for mid to late-stage glaucoma treatment. This product is notable for its ultrathin design, being 20 times thinner than a human hair, which facilitates a less invasive insertion procedure that reduces operating time and simplifies follow-up care. VisiPlate is constructed from alumina, a material recognized for its use in hip replacements, thus ensuring biocompatibility. Founded in 2017 and headquartered in Philadelphia, Pennsylvania, Avisi Technologies aims to address the challenges associated with current glaucoma treatments, including patient non-compliance and post-operative complications, ultimately striving to prevent blindness in affected individuals.
Tmunity Therapeutics, Inc. is a bio-therapeutics company based in Philadelphia, Pennsylvania, focused on developing innovative immunotherapies for cancer, infectious diseases, and autoimmune disorders. Founded in 2015, the company specializes in harnessing the potential of T cells through the creation of novel T Cell Receptor (TCR) engineered T cells, regulatory T cells (Treg), and universal engineered T cell platforms. These products are designed to provide superior control over T cell activation and direction in vivo. Tmunity employs proprietary technologies for the activation, expansion, and genetic engineering of T cells derived from peripheral blood, cord blood, and tumors. The company's expert founding team has extensive experience in T-cell biology, manufacturing, regulatory affairs, and clinical development, enabling them to efficiently advance personalized next-generation immunotherapies into clinical trials. Tmunity's robust manufacturing platform has demonstrated success in supporting multi-center clinical studies across a variety of therapeutic areas.
rePurpose Global, Inc. is a New York-based company founded in 2016 that specializes in a plastic credit platform aimed at reducing plastic waste and promoting environmental sustainability. The organization provides a simple mechanism for individuals and businesses to achieve a Plastic Neutral status by financing projects that remove plastic waste from ecosystems. For every $0.50 contributed, rePurpose Global facilitates the removal of 1 kilogram of plastic that would otherwise harm the environment. Operating through a Global Solutions Network, the company collaborates with various plastic recovery projects across seven countries to enhance their environmental impact and support innovative solutions for waste management. Additionally, its subsidiary in India focuses on urban waste management consulting and educational initiatives to raise awareness about environmental issues among middle school students.
Tmunity Therapeutics, Inc. is a bio-therapeutics company based in Philadelphia, Pennsylvania, focused on developing innovative immunotherapies for cancer, infectious diseases, and autoimmune disorders. Founded in 2015, the company specializes in harnessing the potential of T cells through the creation of novel T Cell Receptor (TCR) engineered T cells, regulatory T cells (Treg), and universal engineered T cell platforms. These products are designed to provide superior control over T cell activation and direction in vivo. Tmunity employs proprietary technologies for the activation, expansion, and genetic engineering of T cells derived from peripheral blood, cord blood, and tumors. The company's expert founding team has extensive experience in T-cell biology, manufacturing, regulatory affairs, and clinical development, enabling them to efficiently advance personalized next-generation immunotherapies into clinical trials. Tmunity's robust manufacturing platform has demonstrated success in supporting multi-center clinical studies across a variety of therapeutic areas.
Grand Round Table Inc. is a developer of clinical decision support tools aimed at enhancing diagnostic accuracy for healthcare providers. The company's flagship system, Grand Round Table, integrates with electronic health records to assist doctors in diagnosing patients by comparing their cases against a comprehensive database of deidentified health records, case reports, and evidence-based medical literature, including resources from the University of Pennsylvania. This technology enables physicians to access insights from previous cases, facilitating quicker and more informed treatment decisions for complex patients. By streamlining the decision-making process, Grand Round Table helps hospitals and clinics reduce unnecessary tests, ineffective treatments, and consultations, ultimately saving time and costs in patient care. Established in 2011, the company is headquartered in Philadelphia, Pennsylvania.